Tumor progression while on chemotherapy: a contraindication to liver resection for multiple colorectal metastases?
about
Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trialMissing metastases as a model to challenge current therapeutic algorithms in colorectal liver metastasesAssociating liver partition and portal vein ligation for staged hepatectomy: From technical evolution to oncological benefitPharmacologic resistance in colorectal cancer: a reviewTherapeutic strategies for synchronous and multiple liver metastases from colorectal cancerRole of surgery in colorectal cancer liver metastasesMulti-modality treatment of colorectal liver metastasesSurgery for colorectal liver metastases: The evolution of determining prognosisRecent Advances in Chemotherapy and Surgery for Colorectal Liver MetastasesResponse biomarkers: re-envisioning the approach to tailoring drug therapy for cancerUnresolved issues and controversies surrounding the management of colorectal cancer liver metastasisYttrium-90 radioembolization for colorectal cancer liver metastases in KRAS wild-type and mutant patients: Clinical and ccfDNA studies.'Liver-first' approach for metastatic colorectal cancer.Locoregional surgical and interventional therapies for advanced colorectal cancer liver metastases: expert consensus statements.Selection for hepatic resection of colorectal liver metastases: expert consensus statementRole of neoadjuvant chemotherapy in resectable synchronous colorectal liver metastasis; An international multi-center data analysis using LiverMetSurvey.Combined liver resection and reconstruction of the supra-renal vena cava: the Paul Brousse experience.The role of primary tumour resection in patients with stage IV colorectal cancer.Importance of response to neoadjuvant chemotherapy in potentially curable colorectal cancer liver metastases.Patterns of chemotherapy-induced hepatic injury and their implications for patients undergoing liver resection for colorectal liver metastases.A phase II experience with neoadjuvant irinotecan (CPT-11), 5-fluorouracil (5-FU) and leucovorin (LV) for colorectal liver metastases.Impact of neoadjuvant chemotherapy with FOLFOX/FOLFIRI on disease-free and overall survival of patients with colorectal metastases.Defining patient outcomes in stage IV colorectal cancer: a prospective study with baseline stratification according to disease resectability statusTwo-stage hepatectomy (R0) with portal vein ligation--towards curing patients with extended bilobular colorectal liver metastases.Tumor marker evolution: comparison with imaging for assessment of response to chemotherapy in patients with colorectal liver metastases.Oxaliplatin, irinotecan and capecitabine as first-line therapy in metastatic colorectal cancer (mCRC): a dose-finding study and pharmacogenomic analysis.Survival Impact of Primary Tumor Lymph Node Status and Circulating Tumor Cells in Patients with Colorectal Liver Metastases.Two-stage strategy for patients with extensive bilateral colorectal liver metastases.Pathological response grade of colorectal liver metastases treated with neoadjuvant chemotherapySelection criteria for radiofrequency ablation for colorectal liver metastases in the era of effective systemic therapy: a clinical score based proposal.Surgical management of colorectal cancer metastases to the liver: multimodality approach and a single institutional experience.Identification of prognostic inflammatory factors in colorectal liver metastases.Association of computed tomography morphologic criteria with pathologic response and survival in patients treated with bevacizumab for colorectal liver metastases.Cetuximab plus chronomodulated irinotecan, 5-fluorouracil, leucovorin and oxaliplatin as neoadjuvant chemotherapy in colorectal liver metastases: POCHER trialRegenerative nodular hyperplasia of the liver related to chemotherapy: impact on outcome of liver surgery for colorectal metastasesSurvival after liver resection in metastatic colorectal cancer: review and meta-analysis of prognostic factors.Colorectal hepatic metastasis: Evolving therapies.High survival rate after two-stage resection of advanced colorectal liver metastases: response-based selection and complete resection define outcomeFOLFOX6 and bevacizumab in non-optimally resectable liver metastases from colorectal cancer.Selective Internal Radiation Therapy (SIRT) with yttrium-90 resin microspheres plus standard systemic chemotherapy regimen of FOLFOX versus FOLFOX alone as first-line treatment of non-resectable liver metastases from colorectal cancer: the SIRFLOX s
P2860
Q24647888-9FFBFE46-0F56-4E68-9D77-CD4336845587Q26751389-29CD17B7-2562-45E9-BB2D-A3B666E96006Q26765218-C1B790F8-1827-4B83-B63B-6646AB4E14F2Q26769850-E5E43462-04EC-441F-A76B-29420FC23FC5Q26829522-CFCF4722-9BA3-4042-A877-BDBF650E48D2Q26830444-546D09ED-BBE7-4A46-AB4B-6C21BF4EFB66Q27006832-03FAC7BF-C967-4398-BDA4-FFDDE12E7F7DQ27694490-FE255F83-24C7-4647-BF30-260B5239CDE0Q28067408-B976926B-7575-4947-B3A0-5CC64EE39B6AQ28074295-6B8F664A-FA2B-42EE-804A-DDDF30C1E6FDQ28085651-55E93AF3-A97E-42B0-B849-FE0F6249783DQ30353464-29F169F8-DD55-48A8-B378-0BFE6F5C6098Q30373308-0A36464C-4551-4D7B-9DA8-E5B8538DC51BQ30415022-BD619376-082C-4501-BCFA-854A6000C1F1Q30415026-0BF0B0B7-ABF1-490B-A2A7-443445530EB5Q30930073-06340EEE-33AF-439C-96AB-6EB0E3007527Q33247711-E45FEF2C-E10A-4D9C-BE70-E89C1A94102DQ33284711-42997715-946B-4C70-8BAB-02097C3A8F4AQ33330997-4E347B57-43D5-493F-8349-2D824B7B9EF4Q33394252-1B170A98-5899-4D1B-AE18-861D408AFEB1Q33448992-3BEEED98-EADA-4B31-98D1-70BA85529469Q33621031-15543A75-582F-46D4-9ECF-D072BDC9ED7DQ33630882-277648C1-4A7D-4E3A-85F6-BCE3A879AB42Q33690475-C9A696A0-4751-4ABE-B3EA-50391C81A3C9Q33735465-1757C01E-222B-4946-BF1F-A1CFBDB8D81EQ33747440-0FC8ACAF-90ED-4D0B-8575-A3398320FEEFQ33854762-3668CA1F-53E1-4E4C-95CC-DB4F35EC511BQ33865026-BB5C5027-0860-4992-A850-E8ED6E6C2D2BQ33865047-530CB046-BC7E-4998-B5E1-4829EDB86E8DQ33906344-C93337C3-8CC9-424B-9481-BC9EB2723C1FQ34013522-2BAA68F1-07DD-4B85-8857-35E9549E67AAQ34017917-5465B97E-66DD-401E-8154-87D9C9466641Q34070129-5EE714D1-A08B-444A-9E68-DA7D3311008CQ34344019-DAD4088E-36FD-4796-A830-DE7459E0AABBQ34601615-5AA68C5D-0076-4C52-83E6-A3B993508E81Q34645408-CB24C639-2BE3-4E1A-9864-B35C4AE6E818Q34663557-01261373-1BAC-4CE2-A3D0-556B9C4A04D4Q34743458-DEB6CD1C-1F5C-4AE6-A14B-0A6987171389Q34745831-5FB88E23-D513-4738-8736-5A9B391FAA93Q34894115-9464F0C6-33EE-4075-AA7E-D32D4D988C49
P2860
Tumor progression while on chemotherapy: a contraindication to liver resection for multiple colorectal metastases?
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Tumor progression while on che ...... ultiple colorectal metastases?
@en
Tumor progression while on che ...... ultiple colorectal metastases?
@nl
type
label
Tumor progression while on che ...... ultiple colorectal metastases?
@en
Tumor progression while on che ...... ultiple colorectal metastases?
@nl
prefLabel
Tumor progression while on che ...... ultiple colorectal metastases?
@en
Tumor progression while on che ...... ultiple colorectal metastases?
@nl
P2093
P2860
P1433
P1476
Tumor progression while on che ...... ultiple colorectal metastases?
@en
P2093
Bernard Paule
Daniel Azoulay
Francis Levi
Gerard Pascal
Henri Bismuth
Valerie Delvart
P2860
P304
1052-61; discussion 1061-4
P356
10.1097/01.SLA.0000145964.08365.01
P407
P577
2004-12-01T00:00:00Z